Research Article

A Comparison between Three-Dimensional Visualization Guided Hepatectomy and Ultrasonography Guided Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma within the Milan Criteria

Tian-pei Guan,1 Chi-hua Fang,1 Jian Yang,1 Nan Xiang,1 Qing-shan Chen,1 and Shi-zhen Zhong2

1Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China
2The Clinical Anatomy Institute, Southern Medical University, Guangzhou, Guangdong 510515, China

Correspondence should be addressed to Chi-hua Fang; fangchi_dr@163.com

Received 14 December 2015; Revised 14 April 2016; Accepted 18 April 2016

Academic Editor: Luca Miele

Copyright © 2016 Tian-pei Guan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Treatment selection for small hepatocellular carcinoma (sHCC) is controversial. We aimed to compare the outcomes of medical imaging three-dimensional visualization system (MI-3DVS) guided surgical resection (SR) and ultrasonography guided radiofrequency ablation (RFA) for sHCC.

Methods. In total, 194 patients who underwent SR or RFA in our hospital between January 2006 and May 2010 were retrospectively enrolled. Overall survival (OS), recurrence-free survival (RFS), and postoperative complications were compared. Cox regression was used to estimate the benefits of MI-3DVS-guided SR on OS and RFS.

Results. Ninety-two patients underwent SR and 102 underwent RFA. The SR group experienced more complications (41.3% versus 19.6%) and longer hospital stay (18.04 ± 7.11 versus 13.06 ± 5.59) (both \( p < 0.05 \)). The 1-, 2-, 3-, 4-, and 5-year OS was 96.7%, 95.7%, 93.5%, 83.5%, and 61.1% in the SR group and 95.0%, 88.1%, 72.7%, 56.9%, and 39.5% in the RFA group. Corresponding RFS was 95.7%, 94.6%, 84.7%, 59.8%, and 40.2% in SR group and 91.2%, 80.3%, 60.5%, 32.3%, and 22.3% in RFA group. The 5-year OS and RFS were higher in SR group (both \( p < 0.001 \)). Interestingly, there was no significance in OS and RFS among subgroups aged >60 years. Independent predictors of OS and RFS, respectively, were intervention (HR, 2.769 and 1.933), tumor number (HR, 5.128 and 3.903), and serum alpha-fetoprotein (AFP) (HR, 1.871 and 1.474) (all \( p < 0.05 \)).

Conclusions. MI-3DVS based hepatectomy should be considered primary treatment while RFA can be treated as alternative therapy for older patients. Intervention, tumor number, and AFP are independent predictors for both survival and recurrence.

1. Introduction

Hepatocellular carcinoma (HCC) is the second leading cause of cancer associated death worldwide [1]. Although Asian countries account for more than 70% of HCC cases [2], rising trends in morbidity and mortality in Western countries have been reported [1, 3]. Surgical resection (SR), transplantation, and radiofrequency ablation (RFA) are recommended as curative methods for patients at the early stage in the Barcelona Clinic Liver Cancer system [4] and those who meet the Milan criteria [2, 5]. RFA is characterized by high cost-effectiveness and minimal invasiveness while SR is considered a high-risk intervention. To reduce the performance-related risks, several surgery planning software systems have been developed [6–8]. To the best of our knowledge, the long-term outcomes of these technique based SR have not been analyzed. This study aimed to compare the outcomes of medical imaging three-dimensional visualization system (MI-3DVS, patented by the authors; software copyright number 2008SR18798) based SR and RFA in patients with sHCC who met the Milan criteria and to identify the predictors of survival and recurrence.
2. Material and Methods

2.1. Patients and Definitions. HCC patients who underwent MI-3DVS based SR or ultrasonography guided RFA as the initial treatment in Zhujiang Hospital between January 2006 and May 2010 and met the eligibility criteria were retrospectively enrolled. The diagnosis of HCC was mainly based on typical features such as arterial hypervascularity and wash out in the early or delayed venous phase on 4-phase contrast-enhanced computed tomography (CT) or dynamic contrast-enhanced magnetic resonance imaging (MRI) [4]. Ultrasonography or CT-guided biopsy was performed when the diagnosis was dubious according to the practice guidelines [4, 9]. Tumor number and diameter were calculated based on the MI-3DVS and/or CT/MRI findings as previously reported [7]. The severity of postoperative complications was estimated according to the Clavien-Dindo Classification system [10]. Demographic and clinical data were retrieved from the hospital's data center. Tumor recurrence was defined as the emergence of lesions within the liver parenchyma or outside the liver at least 4 weeks after treatment.

Eligibility criteria were as follows: (1) meeting the Milan criteria (single HCC \( \leq 5 \) cm or no more than 3 lesions with the largest nodule \( \leq 3 \) cm in diameter); (2) no evidence of extrahepatic metastasis or vascular invasion or extensive lymph node metastasis; (3) Child-Pugh liver function class A or B; (4) no history of encephalopathy, refractory ascites, or variceal bleeding; and (5) no history of anticancer treatment.

2.2. Follow-Up. The main endpoints of this study were cumulative OS, recurrence-free survival (RFS), and postoperative complications. The patients were routinely required to revisit our hospital for follow-up 4 weeks after treatment. Then, serum alpha-fetoprotein (AFP) levels were measured and ultrasonography was performed every 2-3 months for 2 years and then every 6 months for up to 5 years. When intrahepatic recurrence was equivocal, MRI or contrast-enhanced CT was performed. In patients with suspected extrahepatic recurrence, chest CT or positron emission tomography was performed. Once recurrence was confirmed, hepatectomy, RFA, percutaneous ethanol injection (PEI), transcatheater hepatic arterial chemoembolization (TACE), or treatment with sorafenib was recommended.

2.3. Three-Dimensional Visualization and Surgery Planning. The process of three-dimensional (3D) reconstruction and the requirements of the CT dataset by the system have been described previously [7, 11]. The enhanced thin CT slices (2 mm) were automatically registered by the software. Based on the CT data, a 3D model and corresponding individual Couinaud’s anatomic segmentation of the liver could be successfully reconstructed by MI-3DVS according to the distribution area of the hepatic vein and the shape of the portal vein. After that, the 3D liver models were derived as a Standard Template Library file and imported to the Free Form Modeling System (SensAble Technologies, Inc., TextureKiln, USA) to visualize the regions of interest such as the hepatic artery blood supply, location of the HCC, and vascular variations. The total volume and remnant volume of the liver after tumor resection as well as the percentage of the remnant liver were automatically calculated by the measurement tool attached to the Free Form Modeling System. Then, an appropriate strategy was decided according to these parameters. While the operation was performed, the reconstructed models as well as the planned heptatectomy were displayed on a portable computer in the operating room to provide indirect guidance.

2.4. Radiofrequency Ablation. RFA was carried out using the Radionics Cool-Tip RF Ablation System (Radionics, Burlington, VT, USA) under ultrasonography guidance (ACUSON SEQUOIA™ 512 Ultrasound System, Siemens, Berlin, Germany). The procedure was performed with the patient under local, intravenous, or spinal anesthesia, based on their preference. The placement of the ablation needle was achieved under ultrasonography guidance. After appropriate placement, RFA was activated from 10 W to 120 W with an increase of 10 W per minute. Then, RFA was sustained until a total ablative area of 0.5–1.0 cm over the tumor margin in ultrasonography images or an obvious impedance increase of \( \geq 10 \) \( \Omega \) appeared.

2.5. Statistical Analysis. The sample size was calculated with a 5-year overall survival (OS) rate equal to 60% in the SR group and 40% in the RFA group using Empower Stats software (X&Y Solutions Inc., Boston, USA). The type-I error and power were set at 0.05 and 0.90 for a 2-sided log-rank test. Therefore, at least 75 patients were needed in each group, with an estimated lost to follow-up rate of 20%.

The Student t-test and \( \chi^2 \) tests were employed for continuous data and categorical data. The Mann-Whitney U test was used for the ranked data. The Kaplan-Meier method with the log-rank test was used to generate survival functions and estimate the significance between the groups. Cumulative survival rates were estimated with survival tables using the log-rank test. Bivariate and partial correlation analyses were performed to identify factors associated with OS and RFS. The factors identified by correlation analysis were analyzed by both univariate and multivariate analyses using Cox proportional hazards regression models to identify the risk factors associated with survival and recurrence. Statistical analyses were performed using the SPSS 13.0 for Windows (SPSS Inc., IL, USA). A \( p \) value \(<0.05\) was considered statistically significant.

2.6. Ethics Statement. This study was approved by the Ethics Committee of Zhujiang Hospital, Southern Medical University (Number 2014-GDYK-007). Although written informed consent was not required because of the retrospective study design, the patients were informed that their data would be used for scientific purpose when they were hospitalized.

3. Results

3.1. Patient Characteristics. A total of 194 patients who met the eligibility criteria were enrolled in the present study and analyzed. Among these subjects, 92 (47.4%) underwent SR and 102 (52.6%) underwent RFA. Of the patients, 75
in the SR group and 90 in the RFA group were men. The mean age was 52.48 ± 8.36 years and 54.02 ± 7.66 years in the SR and RFA groups, respectively. 3D models were successfully reconstructed the patients in SR group (Figure 1). The diameter of the lesions in the SR and RFA groups was 3.14 ± 1.06 cm and 3.17 ± 0.91 cm, respectively. In addition, the number of patients with 1, 2, or 3 tumors, respectively, was 67, 18, and 7 in the SR group and 68, 22, and 12 in the RFA group. There were no significant differences in sex, age distribution, tumor number, tumor diameter, liver function, hepatitis virus infection, alcoholism, cirrhosis, and results of blood biochemical tests between the two groups (all \( p > 0.05 \)) (Table 1).

### 3.2. Postoperative Complications and Clavien-Dindo Classification

Patients who underwent liver resection experienced longer hospital stay than those who received RFA (18.04 ± 7.11 versus 13.06 ± 5.59 days, \( p < 0.001 \)). The incidence of procedure-related complications was higher in the SR group than in the RFA group (38/92 versus 20/102, \( p = 0.001 \)). Major complications in the SR group were hydrothorax (4 cases), ascites (7), bile leakage (2), postoperative hemorrhage (1), fever ≥38.5°C for at least 3 days (5), and severe pain (23). Major complications in the RFA group were hydrothorax (2 cases), ascites (2), postoperative hemorrhage (1), hepatic failure (1), massive necrosis (1), pneumothorax (3), fever ≥38.5°C for at least 3 days (2), and severe pain (8). Additionally, the rate of moderate-severe complications (Clavien-Dindo class ≥ grade 2) in the SR group was significantly higher than in the RFA group (19/92 versus 4/102, \( p < 0.001 \)). Further details regarding postoperative complications are presented in Table 2.

### 3.3. Overall Survival and Recurrence-Free Survival

The median (quartile range) follow-up periods in the SR and RFA groups were 60 (50–60) months and 48.5 (28–60) months, respectively. During this period, 23 patients (9 in the SR group and 14 in the RFA group) were lost to follow-up, and 94 patients (35 in the SR group and 59 in the RFA group) died of HCC-related disease. The major causes of death were tumor progression, liver failure, massive hemorrhage, and hepatic encephalopathy. Three patients died because of other reasons (1 for unknown reason in the SR group; 1 suicide and 1 traffic accident in the RFA group). There were no treatment-related deaths in either group during the 3 months after treatment. In total, 124 patients experienced recurrence (52 in the SR group and 72 in the RFA group). Treatments for recurrence are summarized in Table 3.
Table 1: Clinical and demographic characteristics of patients in the two groups.

| Variables                      | SR (n) | RFA (n) | Chi-square | p value |
|--------------------------------|--------|---------|------------|---------|
| Number of cases                | 92     | 102     |            |         |
| Gender (male/female)           | 75/17  | 90/12   |            |         |
| Age (years)                    | 52.48 ± 8.36 | 54.02 ± 7.66 |           |         |
| Cases (age ≤ 60/>60)           | 77/15  | 8220    |            |         |
| Hepatitis                      |        |         |            |         |
| None                           | 12     | 17      |            |         |
| HBV                            | 67     | 73      |            |         |
| HCV                            | 6      | 8       |            |         |
| Both HBV and HCV               | 7      | 4       |            |         |
| Cirrhosis                      | 49     | 49      |            |         |
| Alcoholism                     | 13     | 7       |            |         |
| Diameter (cm)                  | 3.19 ± 0.98 | 3.10 ± 0.88 |           |         |
| Tumor number (1/2/3)           | 67/18/7 | 67/22/13 |            |         |
| ALT (µ/L)                      | 47.05 ± 28.55 | 43.32 ± 28.35 |           |         |
| AST (µ/L)                      | 43.70 ± 28.05 | 49.15 ± 26.65 |           |         |
| Tbil (µmol/L)                  | 14.27 ± 7.44 | 16.52 ± 9.60 |           |         |
| ALB (g/L)                      | 38.00 ± 4.75 | 39.36 ± 4.81 |           |         |
| Hb (g/L)                       | 130.09 ± 17.39 | 132.63 ± 26.28 |           |         |
| PLT (≥1011/L/<1011/L)          | 84/8   | 89/13   |            |         |
| PT (≥15 sec/<15 sec)           | 20/96  | 11/83   |            |         |
| AFP (<400 µg/L/≥400 µg/L)      | 50/42  | 60/42   |            |         |
| Child-Pugh (A/B)               | 79/13  | 83/19   |            |         |
| Hospital stays (days)          | 18.04 ± 7.11 | 13.06 ± 5.59 |           |         |

HBV: hepatitis B virus; HCV: hepatitis C virus; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Tbil: total bilirubin; ALB: albumin; Hb: hemoglobin; PLT: platelet; PT: prothrombin time; AFP: α-fetoprotein.

Table 2: Postoperative complications in the two groups.

| Complication & classification | SR (n) | RFA (n) | Chi-square | p value |
|------------------------------|--------|---------|------------|---------|
| Complications (total)        | 38     | 20      | χ^2 = 10.864 | 0.001  |
| Hydrothorax                  | 4      | 2       |            |         |
| Ascites                      | 7      | 2       |            |         |
| Bile leakage                 | 2      | —       |            |         |
| Postoperative hemorrhage     | 1      | 1       |            |         |
| Hepatic failure              | —      | 1       |            |         |
| Massive necrosis             | —      | 1       |            |         |
| Pneumothorax                 | —      | 3       |            |         |
| Febrile (>38.5°C & >3 days)  | 5      | 2       |            |         |
| Pain (PCA included)          | 23     | 8       |            |         |

Clavien-Dindo Classification  | z = −2.094 | 0.036 |
Grade 1                       | 19      | 16     |
Grade 2                       | 16      | 3      |
Grade 3-4                     | 3       | 1      |

* Mann-Whitney U test;
PCA: patient controlled analgesia.

Table 3: Treatments for tumor recurrence.

| Group | SR (n = 52) | RFA (n = 72) | p value |
|-------|-------------|--------------|---------|
| Without intervention           | 12          | 16           | 0.911   |
| TACE                           | 18          | 17           | 0.179   |
| RFA                            | 9           | 20           | 0.174   |
| PEI                            | 2           | 4            | >0.999  |
| Sorafenib                      | 3           | 5            | >0.999  |
| Second hepatectomy             | 5           | 2            | 0.129   |
| TACE and RFA                   | 3           | 8            | 0.302   |

* Fisher’s exact test.

The corresponding RFS rates were 95.7%, 94.6%, 84.7%, 59.8%, and 40.2% in the SR group and 91.2%, 80.3%, 60.5%, 32.3%, and 22.3% in the RFA group. Both OS and RFS were significantly higher in patients who underwent hepatectomy than in those who received RFA (Figure 2).

Additionally, in the SR group, both OS and RFS were higher among subgroups of patients with solitary HCC ≤ 3 cm, multifocal HCC, solitary HCC > 3 cm, serum AFP level ≥ 400 µg/L, serum AFP level < 400 µg/L, Child-Pugh class A, Child-Pugh class B, and younger patients (aged ≤ 60 years). However, no significant differences in RFS were found in...
Figure 2: Overall survival and recurrence-free survival in the two groups. The 5-year overall survival rates were 61.1% and 39.5% in the SR and RFA groups, respectively. The 5-year recurrence-free survival rates were 40.2% and 22.3% in the SR and RFA groups, respectively. Both overall survival ($p < 0.001$) and recurrence-free survival ($p = 0.002$) were significantly higher in the SR group than in the RFA group. SR, three-dimensional visualization system-guided surgical resection; RFA, radiofrequency ablation.

| Subgroups          | 5-year overall survival rate | p value | 5-year recurrence-free survival | p value |
|--------------------|------------------------------|---------|---------------------------------|---------|
| Solitary > 3 cm    | 51.0% (39)                  | 0.031   | 43.2% (39)                     | 0.037   |
| Multiple tumors    | 38.8% (25)                  | 0.024   | 10.6% (25)                     | 0.164   |
| Solitary ≤ 3 cm    | 92.6% (28)                  | 0.026   | 64.3% (28)                     | 0.007   |
| AFP < 400 μg/L     | 73.6% (50)                  | 0.002   | 50.9% (50)                     | 0.002   |
| AFP ≥ 400 μg/L     | 46.9% (42)                  | 0.008   | 26.8% (42)                     | 0.027   |
| Noncirrhosis       | 67.7% (43)                  | 0.006   | 45.4% (43)                     | 0.005   |
| Cirrhosis          | 55.4% (49)                  | 0.005   | 35.5% (49)                     | 0.013   |
| Child-Pugh A       | 64.8% (69)                  | 0.002   | 42.3% (69)                     | 0.002   |
| Child-Pugh B       | 49.9% (23)                  | 0.034   | 33.6% (23)                     | 0.089   |
| Age ≤ 60 years     | 63.2% (77)                  | <0.001  | 41.2% (77)                     | <0.001  |
| Age > 60 years     | 60.0% (15)                  | 0.814   | 35.6% (15)                     | 0.709   |

Table 4: Overall survival and recurrence-free survival for patients in subgroups.

patients with multiple nodules and Child-Pugh class B and in older patients (aged > 60 years) (Table 4).

3.4. Prognostic Indicators for Survival and Recurrence. The factors associated with OS in correlation analysis (disregarding the strength of the association) were intervention, tumor number, tumor diameter, Child-Pugh class, cirrhosis, serum AFP, and tumor recurrence. The factors associated with RFS were intervention, tumor number, tumor diameter, Child-Pugh class, and serum AFP, respectively (Table 5). These variables were analyzed by using the Cox proportional hazards model to identify the independent predictors of survival and tumor recurrence. By univariate analysis, the factors associated with OS were intervention, tumor number, serum AFP, Child-Pugh class, and tumor recurrence. However, by multivariate analysis, tumor diameter was associated with OS while tumor recurrence, Child-Pugh class, and tumor recurrence were not. The corresponding hazard ratios (HRs) were 2.769 (95% confidence interval (CI): 1.789–4.286, $p < 0.001$) for intervention, 2.166 (95% CI: 1.656–2.835, $p < 0.001$) for
Table 5: Correlation analysis of variables relevant to overall survival and recurrence-free survival.

| Variable            | Overall survival (months) | Recurrence-free survival (months) |
|---------------------|---------------------------|-----------------------------------|
|                     | Related coefficient | p value | Related coefficient | p value |
| Intervention        | −0.325                   | <0.001Δ | −0.312              | <0.001Δ  |
| Gender              | −0.024                   | 0.735   | 0.002               | 0.981    |
| Tumor number        | −0.590                   | <0.001  | −6.16               | <0.001   |
| PLT                 | −0.056                   | 0.437   | −0.076              | 0.290    |
| PT                  | −0.031                   | 0.671   | −0.005              | 0.941    |
| Hepatitis           | 0.005                    | 0.945   | −0.009              | 0.900    |
| AFP                 | −0.165                   | 0.022Δ  | −0.209              | 0.004Δ   |
| Cirrhosis           | −0.179                   | 0.012Δ  | −0.123              | 0.087    |
| Child-Pugh class    | −0.206                   | 0.004Δ  | −0.164              | 0.023Δ   |
| Alcoholism          | 0.050                    | 0.489   | −0.008              | 0.908    |
| Tumor diameter      | −0.381                   | <0.001  | −0.340              | <0.001   |
| Tumor recurrence    | −0.234                   | 0.001Δ  | —                   | —        |
| Age (years)         | −0.096                   | 0.185   | −0.059              | 0.414    |
| ALT (μ/L)           | 0.078                    | 0.280   | 0.087               | 0.226    |
| AST (μ/L)           | 0.037                    | 0.612   | 0.059               | 0.441    |
| Tbi (μmol/L)        | 0.074                    | 0.305   | 0.047               | 0.513    |
| ALB (g/L)           | 0.072                    | 0.321   | 0.047               | 0.517    |
| Hb (g/L)            | 0.042                    | 0.559   | 0.004               | 0.957    |

* Spearman correlation coefficient; † Pearson correlation coefficient; ‡ partial correlations: diameters/tumor number were controlled while tumor number/diameters were analyzed. Δ Correlation is significant at the 0.01 level (2-tailed). △ Correlation is significant at the 0.001 level (2-tailed). PLT: platelet; PT: prothrombin time; AFP: α-fetoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Tbi: total bilirubin; ALB: albumin; Hb: hemoglobin.

Table 6: Univariate and multivariate analyses for overall survival.

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | Score               | p value               | HR (95% CI)     | p value |
| Survival                   |                     |                       |                  |
| Intervention (RFA versus SR)| 14.118              | <0.001                | 2.769 (1.789–4.286) | <0.001 |
| Hepatitis virus infection | 6.798               | 0.079                 |                   |        |
| HBV                        | 6.598               | 0.010                 |                   |        |
| HCV                        | 2.421               | 0.120                 |                   |        |
| Both HBV and HCV           | 0.531               | 0.466                 |                   |        |
| Liver cirrhosis            | 1.968               | 0.161                 |                   |        |
| Diameter (cm)              | 2.947               | 0.086                 | 2.166 (1.656–2.835) | <0.001 |
| Tumor number               | 61.910              | <0.001                | 5.128 (3.548–7.413) | <0.001 |
| AFP (≥400 μg/L versus <400 μg/L) | 10.157             | 0.001                | 1.871 (1.229–2.847) | 0.003  |
| Child-Pugh (B versus A)    | 5.201               | 0.023                 |                   |        |

HR: hazard ratio; SR: three-divisional visualization system-guided surgical resection; RFA: radiofrequency ablation; HBV: hepatitis B virus; HCV: hepatitis B virus; AFP: α-fetoprotein.

tumor diameter (cm), 5.128 (95% CI: 3.548–7.413, p < 0.001) for tumor number, and 1.871 (95% CI: 1.229–2.847, p = 0.003) for serum AFP.

By univariate analysis, the factors associated with RFS were intervention, tumor number, serum AFP, Child-Pugh class, and tumor recurrence. However, by multivariate analysis, Child-Pugh class was not associated with RFS while tumor diameter was. The corresponding HRs for intervention, tumor number, tumor diameter, and serum AFP were 1.933 (95% CI: 1.340–1.789, p < 0.001), 3.903 (95% CI: 2.819–5.404, p < 0.001), 1.411 (95% CI: 1.132–1.759, p = 0.002), and 1.474 (95% CI: 1.023–2.126, p = 0.038), respectively. Further details are provided in Tables 6 and 7.

4. Discussion

HCC is the sixth most common malignancy and the second leading cause of cancer associated death globally [1, 12]. Liver
transplantation, RFA, and liver resection are recommended curative methods for HCC by the European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer, and the American Association for the Study of Liver Diseases guidelines [4, 9]. However, SR remains to be the preferred treatment for HCC because of donor scarcity, especially in Asian countries [2, 7]. Tumor number and size and underlying disease as well as venous and/or artery variations play an important role in treatment decisions, especially in patients with combined cirrhosis [13], for whom more remnant volume should be reserved to ensure the safety of the surgery. Severe surgery-related complications such as liver dysfunction and bile leakage are closely associated with improper management of the intrahepatic vessels during the operation [14]. Comprehensive understanding of the tumor characteristics and adjacent structures is critical for successful patient management [11, 15, 16]. Developments in computer science and its integration with medical imaging technology offer a novel opportunity to reduce these adverse events by visualizing the intrahepatic vessels and optimizing resection schemes on individual 3D models. The application of MI-3DVS in observing the origin, bifurcations, and anatomical variations of blood vessels and the relationship between the tumor and crucial surrounding structures have been described previously [17–20]. This technology plays an important role in volumetric analysis and characterizing the anatomical features of hepatolithiasis, liver cancer, and pancreatic disease [7, 8, 17, 21]. In other words, major drawbacks of conventional hepatectomy, such as compromised liver function and high incidence of complications could be overcome or at least minimized through adequate preservation of liver parenchyma and comprehensive preoperative evaluation. The present study showed that sHCC patients who meet the Milan criteria could benefit more from MI-3DVS-guided SR than RFA in terms of better survival and lower recurrence rate.

The results of our study showed that patients who underwent SR experienced longer hospital stay than those who received RFA. Consistent with previous studies [22–25], the incidence of procedure-related complications as well as the rate of serve complications in the SR group was significantly higher than that in the RFA group. Interestingly, the incidence of procedure-related severe adverse events (grade III-IV) in the present study, such as bile leakage, postoperative hemorrhage hydrothorax, and hepatic failure, was much lower than that reported in patients who underwent conventional heptectomy for HCC in a randomized prospective clinical trial [3/92 versus 13/100, resp.] [26]. This difference may be explained by the fact that the MI-3DVS allows preoperative planning. The 3D model of the MI-3DVS facilitates the localization of lesions and identification of crucial anatomical relationships with adjacent vessels that lead to an accurate and fluent procedure. Furthermore, the shortcomings of CT and/or MRI images, which are used as a guide for conventional hepatectomy, can be overcome with more intuitive and multidirectional anatomical information provided by the MI-3DVS. Therefore, the incidence of postoperative complications could be minimized with more parenchyma reservation, less hepatic blood occlusion, and shorter operative duration.

After recurrence was diagnosed, although suitable treatments such as RFA, TACE, second hepatectomy, PEI, and sorafenib were suggested, more than 20% of patients in each group rejected additional intervention. The 5-year OS and RFS were 61.1% and 40.2% in the SR group and 39.5% and 22.3% in the RFA group, respectively. It has been reported that the 5-year OS was 60–80% in patients who underwent liver resection [26–28] and 40–70% in those who received RFA [28, 29]. The results of OS in patients who underwent MI-3DVS-guided SR in the present study were consistent with these randomized prospective trials on conventional liver resection. HCC disseminates through portal and hepatic veins and spreads in the same liver segments [30, 31]. Therefore, anatomical hepatectomy has been widely accepted by surgeons because safe resection margins for HCC can be achieved (theoretically, 1-2 cm outside the tumor margin), eliminating both primary lesions and microdisseminations simultaneously [32]. A prospective study with a larger sample size will be performed to compare the benefits of MI-3DVS-guided hepatectomy and conventional resection. For RFA,
repeat insertions and ablations are needed for larger tumors. Secondly, the procedure depends greatly on the guidance of 2-dimensional ultrasonography to obtain an ideal ablative area in a 3-dimensional level. Furthermore, the invasiveness and proliferation ability of the tumor cells at the periphery may be accelerated if RFA is incomplete [33]. Thus, the advantage of MI-3DVS-guided liver resection over RFA for small HCC could be the result of a more successful eradication.

The RFS of the RFA group in the present study was similar to that reported in previous clinical trials [26, 27] and lower than that reported in two larger sample size multicenter retrospective studies. This disadvantage may have been caused by the higher number of patients with multifocal HCC (34/102 versus 183/1305) [34] and those with serum AFP ≥ 400 μg/L (42/102 versus 34/319) [35] in the present study. Additionally, the poor access to adequate treatment facilities caused by the lower income level than that of developed countries could also be a reason for this difference to some extent [36].

As multiple lesions exist in cases of solitary HCC ≤ 3 cm only according to the Milan criteria, we divided the patients into three subgroups in which both tumor number and size were considered (solitary HCC ≤ 3 cm, solitary HCC > 3 cm and ≤5 cm, and multiple lesions) when survival analysis was performed rather than dividing the patients according to tumor number or diameter only. At the same time, this grouping method was adequate considering the superiority of RFA in ablating lesions no more than 3 cm in diameter [37]. The results of survival analysis between subgroups demonstrated that patients benefit more from hepatectomy than from RFA except for OS in older patients (aged > 60 years) and RFS in patients with multiple lesions and Child-Pugh class B and in older patients (aged > 60 years). Thus, RFA may be more suitable for older patients [29].

Factors associated with OS in bilateral correlation analysis were intervention, tumor number, tumor diameter, serum AFP, liver cirrhosis, Child-Pugh class, and tumor recurrence. Corresponding parameters associated with RFS were intervention, tumor number, tumor diameter, serum AFP, and Child-Pugh class. Recently, a study suggested that hepatitis virus was an independent prognostic factor in HCC patients [34]. Hence, we included hepatitis virus infection as a potential factor associated with prognosis when Cox regression analyses were performed, although there was no significant correlation between hepatitis and survival in the correlation analysis. The final Cox hazards model of our study demonstrated that independent predictive parameters for both OS and RFS were intervention, tumor number, and serum AFP. Recent publications indicated that older age and liver cirrhosis were risk factors associated with OS [34, 38, 39]. This difference could have been caused by the relatively small sample size as well as the epidemiologic characteristics in the current study.

The present study has some limitations. First, the present study is limited by the retrospective study design, and the significance of the findings is not as strong as that provided by prospective studies or other study designs [40, 41]. Second, some patients received additional therapies such as RFA, TACE, and sorafenib because of tumor recurrence after initial treatment during the follow-up period. Thus, the OS may be cofounded to some extent by the availability of adequate medical services, although there was no significant difference between the two groups, especially for the subjects with lower income who tend to request RFA. Third, the comparison of long-term outcomes of MI-3DVS-guided hepatectomy and conventional liver resection was not assessed in the present study because a larger sample size was needed. Finally, some commonly accepted parameters associated with poor survival, such as histological differentiation and tumor staging, were not analyzed because not enough data were available in the RFA group.

5. Conclusion

MI-3DVS-guided hepatectomy should be considered as the primary treatment for HCC patients with multifocal disease, higher AFP level, and preserved liver function within the Milan criteria. However, for older candidates, RFA can be considered as an alternative therapy, as it could lead to comparable survival but shorter hospital stay and lower incidence of complications. Intervention, tumor number, and serum AFP are important and independent prognostic predictors of both survival and recurrence.

Competing Interests

The authors declare that the MI-3DVS patent is owned by the authors, and there are no competing interests regarding both the patent and the publication of this paper.

Acknowledgments

This paper was supported by (1) the National High Technology Research and Development Program of China (863 Program) (Grant no. 2012AA021105) and (2) the United Fund of National Natural Science Foundation of China and Government of Guangdong Province (Grant no. U1401254).

References

[1] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015.
[2] D. Poon, B. O. Anderson, L.-T. Chen et al., “Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009,” The Lancet Oncology, vol. 10, no. 11, pp. 1111–1118, 2009.
[3] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015.
[4] J. Bruix and M. Sherman, “Management of hepatocellular carcinoma: an update,” Hepatology, vol. 53, no. 3, pp. 1020–1022, 2011.
[5] K. Kurokohchi, S. Watanabe, T. Masaki et al., “Combined use of percutaneous ethanol injection and radiofrequency ablation for the effective treatment of hepatocellular carcinoma,” International Journal of Oncology, vol. 21, no. 4, pp. 841–846, 2002.
[6] A. L. Simpson, D. A. Geller, A. W. Hemmings et al., “Liver planning software accurately predicts postoperative liver volume and measures early regeneration,” *Journal of the American College of Surgeons*, vol. 219, no. 2, pp. 199–207, 2014.

[7] C.-H. Fang, H.-S. Tao, J. Yang et al., “Impact of three-dimensional reconstruction technique in the operation planning of centrally located hepatocellular carcinoma,” *Journal of the American College of Surgeons*, vol. 220, no. 1, pp. 28–37, 2015.

[8] T. Takamoto, T. Hashimoto, S. Ogata et al., “Planning of anatomical liver segmentectomy and subsegmentectomy with 3-dimensional simulation software,” *The American Journal of Surgery*, vol. 206, no. 4, pp. 530–538, 2013.

[9] European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, “EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma,” *Journal of Hepatology*, vol. 56, no. 4, pp. 908–943, 2012.

[10] P. A. Clavien, J. Barkun, M. L. de Oliveira et al., “The Clavien-Dindo classification of surgical complications: five-year experience,” *Annals of Surgery*, vol. 250, no. 2, pp. 187–196, 2009.

[11] C.-H. Fang, J. Liu, Y.-F. Fan, J. Yang, N. Xiang, and N. Zeng, “Outcomes of hepatectomy for hepatolithiasis based on 3-dimensional reconstruction technique,” *Journal of the American College of Surgeons*, vol. 217, no. 2, pp. 280–288, 2013.

[12] Z. Huang, P. Zhang, H. Wang, L. Yan, and W. Wang, “Comparing outcomes of two vascular inflow occlusion techniques and treatment without vascular occlusion during major hepatectomy in patients with Hepatitis B–related hepatocellular carcinoma,” *PloS ONE*, vol. 9, no. 9, Article ID e107303, 2014.

[13] J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” *The Lancet*, vol. 362, no. 9399, pp. 1907–1917, 2003.

[14] Q.-J. Ou and R. E. Hermann, “The role of hepatic veins in liver operations,” *Surgery*, vol. 95, no. 4, pp. 381–391, 1984.

[15] C.-H. Fang, X.-F. Li, Z. Li et al., “Application of a medical image processing system in liver transplantation,” *Hepatobiliary and Pancreatic Diseases International*, vol. 9, no. 4, pp. 370–375, 2010.

[16] S. Nakamura and T. Tsuzuki, “Surgical anatomy of the hepatic veins and the inferior vena cava,” *Surgery Gynecology and Obstetrics*, vol. 152, no. 1, pp. 43–50, 1981.

[17] C.-H. Fang, D. Kong, X. Wang et al., “Three-dimensional reconstruction of the peripancreatic vascular system based on computed tomographic angiography images and its clinical application in the surgical management of pancreatic tumors,” *Pancreas*, vol. 43, no. 3, pp. 389–395, 2014.

[18] J. Yang, C.-H. Fang, Y.-F. Fan et al., “To assess the benefits of medical image three-dimensional visualization system assisted pancreaticoduodenectomy for patients with hepatic artery variance,” *International Journal of Medical Robotics and Computer Assisted Surgery*, vol. 10, no. 4, pp. 410–417, 2014.

[19] C.-H. Fang, W. Zhu, H. Wang et al., “A new approach for evaluating the resectability of pancreatic and peripanillary neoplasms,” *Pancreatology*, vol. 12, no. 4, pp. 364–371, 2012.

[20] C.-H. Fang, J.-H. You, W. Y. Lau et al., “Anatomical variations of hepatic veins: three-dimensional computed tomography scans of 200 subjects,” *World Journal of Surgery*, vol. 36, no. 1, pp. 120–124, 2012.

[21] A. Xie, C. Fang, Y. Huang, Y. Fan, J. Pan, and F. Peng, “Application of three-dimensional reconstruction and visible simulation technique in reoperation of hepatolithiasis,” *Journal of Gastroenterology and Hepatology*, vol. 28, no. 2, pp. 248–254, 2013.

[22] M. A. Chinnaratha, D. Sathananthan, P. Pateria et al., “High local recurrence of early-stage hepatocellular carcinoma after percutaneous thermal ablation in routine clinical practice,” *European Journal of Gastroenterology and Hepatology*, vol. 27, no. 3, pp. 349–354, 2015.

[23] P. H. Liu, C. Y. Hsu, C. Y. Hsia et al., “Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma ≤ 2 cm in a propensity score model,” *Annals of Surgery*, vol. 62, no. 3, 2015.

[24] I. Gory, M. Fink, S. Bell et al., “Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study,” *Scandinavian Journal of Gastroenterology*, vol. 50, no. 5, pp. 567–576, 2015.

[25] C. Fu, N. Liu, Q. Deng, X. Li, K. Ma, and P. Bie, “Radiofrequency ablation vs. surgical resection on the treatment of patients with small hepatocellular carcinoma: a system review and meta-analysis of five randomized controlled trials,” *Hepato-Gastroenterology*, vol. 61, no. 134, pp. 1722–1729, 2014.

[26] H. Liu, Z. G. Wang, S. Y. Fu et al., “Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria,” *British Journal of Surgery*, vol. 103, no. 4, pp. 348–356, 2016.

[27] J. Huang, L. Yan, Z. Cheng et al., “A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria,” *Annals of Surgery*, vol. 252, no. 6, pp. 903–912, 2010.

[28] M.-S. Chen, J.-Q. Li, Y. Zheng et al., “A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma,” *Annals of Surgery*, vol. 243, no. 3, pp. 321–328, 2006.

[29] M. Pomplii, A. Saviano, N. de Matthaeis et al., “Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤ 3 cm. Results of a multicenter Italian survey,” *Journal of Hepatology*, vol. 59, no. 1, pp. 89–97, 2013.

[30] A. Sasaki, S. Kai, Y. Iwashita, S. Hirano, M. Ohta, and S. Kitano, “Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma,” *Cancer*, vol. 103, no. 2, pp. 299–306, 2005.

[31] A. Toyosaka, E. Okamoto, M. Mitsunobu, T. Oriyama, N. Nakao, and K. Miura, “Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel,” *The American Journal of Gastroenterology*, vol. 91, no. 8, pp. 1610–1615, 1996.

[32] M. Shi, R.-P. Guo, X.-J. Lin et al., “Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial,” *Annals of Surgery*, vol. 245, no. 1, pp. 36–43, 2007.

[33] S. Yoshida, M. Kornek, N. Ikenaga et al., “Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma,” *Hepatology*, vol. 58, no. 5, pp. 1667–1680, 2013.

[34] Y.-S. Kim, H. K. Lim, H. Rhim et al., “Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors,” *Journal of Hepatology*, vol. 58, no. 1, pp. 89–97, 2013.

[35] R. Tateishi, S. Nakao, and K. Miura, “Intrahepatic metastases in hepatocellular carcinoma: analysis of five randomized controlled trials,” *Annals of Surgery*, vol. 62, no. 2, pp. 69–90, 2005.

[36] A. Jemal, F. Bray, M. M. Center et al., “Global cancer statistics,” *CA: A Cancer Journal for Clinicians*, vol. 61, no. 2, pp. 69–90, 2011.
[37] M. Sala, J. M. Llovet, R. Vilana et al., “Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma,” *Hepatology*, vol. 40, no. 6, pp. 1352–1360, 2004.

[38] E. K. Park, H. J. Kim, C. Y. Kim et al., “A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma,” *Annals of Surgical Treatment and Research*, vol. 87, no. 2, pp. 72–80, 2014.

[39] R. Tateishi, S. Shiina, T. Teratani et al., “Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases,” *Cancer*, vol. 103, no. 6, pp. 1201–1209, 2005.

[40] P. C. Austin, “Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies,” *Pharmaceutical Statistics*, vol. 10, no. 2, pp. 150–161, 2011.

[41] R. B. D'Agostino Jr., “Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group,” *Statistics in Medicine*, vol. 17, no. 19, pp. 2265–2281, 1998.